16 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.
Huazhong Agricultural University
Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase.
University of Illinois At Chicago
Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
Meiji Seika Kaisha
Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR).
National Institute of Immunology
FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors.
National Institute of Pharmaceutical Education and Research (NIPER)
Peptidomimetics: An Overview of Recent Medicinal Chemistry Efforts toward the Discovery of Novel Small Molecule Inhibitors.
Ri.Med Foundation
The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
Yonsei University
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
University of London
Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI).
Affinium Pharmaceuticals
2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI.
Affinium Pharmaceuticals
Aniline derivative, pharmaceutical composition containing same, and use thereof
Kissei Pharmaceutical
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Glaxosmithkline
Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
Dupont Pharmaceuticals